Matches in Wikidata for { <http://www.wikidata.org/entity/Q58389083> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- Q58389083 description "article scientifique publié en 2000" @default.
- Q58389083 description "artículu científicu espublizáu n'avientu de 2000" @default.
- Q58389083 description "im Dezember 2000 veröffentlichter wissenschaftlicher Artikel" @default.
- Q58389083 description "scientific article published on 01 December 2000" @default.
- Q58389083 description "wetenschappelijk artikel" @default.
- Q58389083 description "наукова стаття, опублікована в жовтні 2000" @default.
- Q58389083 description "مقالة علمية تنشرت ف 1 دجنبر 2000" @default.
- Q58389083 name "A genotypic analysis of patients receiving Zidovudine with either Lamivudine, Didanosine or Zalcitabine dual therapy using the LiPA point mutation assay to detect genotypic variation at codons 41, 69, 70, 74, 184 and 215" @default.
- Q58389083 name "A genotypic analysis of patients receiving Zidovudine with either Lamivudine, Didanosine or Zalcitabine dual therapy using the LiPA point mutation assay to detect genotypic variation at codons 41, 69, 70, 74, 184 and 215" @default.
- Q58389083 type Item @default.
- Q58389083 label "A genotypic analysis of patients receiving Zidovudine with either Lamivudine, Didanosine or Zalcitabine dual therapy using the LiPA point mutation assay to detect genotypic variation at codons 41, 69, 70, 74, 184 and 215" @default.
- Q58389083 label "A genotypic analysis of patients receiving Zidovudine with either Lamivudine, Didanosine or Zalcitabine dual therapy using the LiPA point mutation assay to detect genotypic variation at codons 41, 69, 70, 74, 184 and 215" @default.
- Q58389083 prefLabel "A genotypic analysis of patients receiving Zidovudine with either Lamivudine, Didanosine or Zalcitabine dual therapy using the LiPA point mutation assay to detect genotypic variation at codons 41, 69, 70, 74, 184 and 215" @default.
- Q58389083 prefLabel "A genotypic analysis of patients receiving Zidovudine with either Lamivudine, Didanosine or Zalcitabine dual therapy using the LiPA point mutation assay to detect genotypic variation at codons 41, 69, 70, 74, 184 and 215" @default.
- Q58389083 P1433 Q58389083-DDACECFA-9BF7-4D85-8AE3-CAD04387750D @default.
- Q58389083 P1476 Q58389083-4B9A849C-6668-40AA-9A44-77AA31E08D71 @default.
- Q58389083 P2093 Q58389083-1B85663A-BF43-41F3-9091-6F74BAB543B1 @default.
- Q58389083 P2093 Q58389083-894EE00F-04C9-465A-8ED6-346EE8EE5EB3 @default.
- Q58389083 P2093 Q58389083-E2D2EDD1-1C96-4502-8656-0ED075168FA6 @default.
- Q58389083 P2860 Q58389083-062FD88C-03BC-425B-8D22-4BFC81E2ED5C @default.
- Q58389083 P2860 Q58389083-10E64BD6-0856-4FD5-8179-CCB976D5BD4D @default.
- Q58389083 P2860 Q58389083-123C684B-4B4F-4508-A141-C91A038D7041 @default.
- Q58389083 P2860 Q58389083-1ECA27E9-2D46-4E3A-A3AC-24556A77CD54 @default.
- Q58389083 P2860 Q58389083-20B12F76-09D8-4D61-A95B-27B799A9E240 @default.
- Q58389083 P2860 Q58389083-2C7E0C55-38C0-4E2E-8D55-662A3B953DAD @default.
- Q58389083 P2860 Q58389083-345707A3-A8CB-4C31-B981-322D84A93816 @default.
- Q58389083 P2860 Q58389083-5C45EC13-9A51-4E97-A924-B29CD177EE0C @default.
- Q58389083 P2860 Q58389083-62DB7A58-1390-4BB4-9924-B37BC42A06D9 @default.
- Q58389083 P2860 Q58389083-73D0D5EB-DBE5-4421-8BD2-DE0BDADDBBE0 @default.
- Q58389083 P2860 Q58389083-7FB4B25D-B2E5-4FB3-8377-F480E32CB92E @default.
- Q58389083 P2860 Q58389083-81430659-0B1D-4190-A2F3-4683CCA699A9 @default.
- Q58389083 P2860 Q58389083-A9CC07A4-04E0-484C-9553-EE29E6092EFB @default.
- Q58389083 P2860 Q58389083-D40AA09A-7B99-4AC4-9E7C-ECA67AB8F694 @default.
- Q58389083 P2860 Q58389083-DAC52D50-B425-485F-B5E9-31218BD001FC @default.
- Q58389083 P304 Q58389083-65958410-8AB4-40DB-9825-013FA6504E10 @default.
- Q58389083 P31 Q58389083-3EF2AA09-7459-4DB0-AD3C-A48A407BF0EA @default.
- Q58389083 P356 Q58389083-110ECA3B-BCE2-4A43-9B74-AA5791477FE9 @default.
- Q58389083 P433 Q58389083-0A5A4419-DBA0-4F55-9FDD-E55FA817986E @default.
- Q58389083 P478 Q58389083-182AC054-3D50-4FD4-A2BD-5BB0D86C9B08 @default.
- Q58389083 P50 Q58389083-E3F22071-ACE7-4328-8BF4-3E1BAC605BA0 @default.
- Q58389083 P577 Q58389083-A86D44D9-CFA9-4E43-A6C4-966BBDAC2E47 @default.
- Q58389083 P698 Q58389083-A1B3463A-C863-41BF-B155-18E1E4F096B4 @default.
- Q58389083 P921 Q58389083-583959E3-E886-4515-B99D-2B6D2BEC2895 @default.
- Q58389083 P921 Q58389083-82CC13B8-BD36-4A9E-8BB7-217BBAFC0A68 @default.
- Q58389083 P921 Q58389083-8900AA8A-DB58-4571-91AC-7ED3D8DEDF0A @default.
- Q58389083 P356 S1386-6532(00)00087-1 @default.
- Q58389083 P698 11090748 @default.
- Q58389083 P1433 Q15759726 @default.
- Q58389083 P1476 "A genotypic analysis of patients receiving Zidovudine with either Lamivudine, Didanosine or Zalcitabine dual therapy using the LiPA point mutation assay to detect genotypic variation at codons 41, 69, 70, 74, 184 and 215" @default.
- Q58389083 P2093 "La Seta Catamancio S" @default.
- Q58389083 P2093 "Parker D" @default.
- Q58389083 P2093 "Sheridan F" @default.
- Q58389083 P2860 Q35132164 @default.
- Q58389083 P2860 Q35828466 @default.
- Q58389083 P2860 Q36339159 @default.
- Q58389083 P2860 Q44034071 @default.
- Q58389083 P2860 Q44310637 @default.
- Q58389083 P2860 Q44443514 @default.
- Q58389083 P2860 Q45256341 @default.
- Q58389083 P2860 Q45751396 @default.
- Q58389083 P2860 Q53353555 @default.
- Q58389083 P2860 Q54128912 @default.
- Q58389083 P2860 Q71120796 @default.
- Q58389083 P2860 Q71545355 @default.
- Q58389083 P2860 Q71545358 @default.
- Q58389083 P2860 Q73048867 @default.
- Q58389083 P2860 Q73186069 @default.
- Q58389083 P304 "135-142" @default.
- Q58389083 P31 Q13442814 @default.
- Q58389083 P356 "10.1016/S1386-6532(00)00087-1" @default.
- Q58389083 P433 "3" @default.
- Q58389083 P478 "19" @default.
- Q58389083 P50 Q40213049 @default.
- Q58389083 P577 "2000-12-01T00:00:00Z" @default.
- Q58389083 P698 "11090748" @default.
- Q58389083 P921 Q198504 @default.
- Q58389083 P921 Q422606 @default.
- Q58389083 P921 Q422631 @default.